clinicaltrialsarena16h
Alleviant Medical secures $90m to launch pivotal aortic stent trial
The $90m will be used to launch the second of two pivotal trials examining the company’s therapy for patients living with heart failure.
clinicaltrialsarena21h
Hengrui and Kailera report best-in-class data from Phase II GLP-1/GIP trial
Topline data from Hengrui’s Phase II trial for its GLP-1/GIP product demonstrated a statistically significant mean weight loss of 22.8%.
clinicaltrialsarena21h
BlueRock accelerates Parkinson’s disease therapy to Phase III
BlueRock has said it is launching the Phase III trials in the first half of this year after Phase I talks with the US FDA.
clinicaltrialsarena22h
JP Morgan 2025: reduced dosing and expanded manufacturing paving way for Amgen’s obesity entrance
Amgen presented data about its obesity drug at JP Morgan 2025, stating it hopes the once-monthly dosing will make it an attractive therapy.